STOCK TITAN

[SCHEDULE 13G/A] Immunocore Holdings plc Amended Passive Investment Disclosure

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. filed Amendment No. 3 to a Schedule 13G/A reporting a sizeable passive stake in Immunocore Holdings plc – ADR. As of 12/31/2025, it beneficially owned 5,961,227 ADRs, representing 11.8% of the outstanding class.

The firm reports sole voting and sole dispositive power over all 5,961,227 ADRs, with no shared voting or dispositive power. It certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Immunocore.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Investment Management, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:02/17/2026
Immunocore Holdings Plc

NASDAQ:IMCR

IMCR Rankings

IMCR Latest News

IMCR Latest SEC Filings

IMCR Stock Data

1.64B
49.40M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United Kingdom
OXFORDSHIRE